Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Rho GTPase Activating Protein 9 (ARHGAP9) in Human Cancers

Author(s): Wenping Song, Jinhua Chen, Shuolei Li, Ding Li, Yongna Zhang, Hanqiong Zhou, Weijiang Yu, Baoxia He, Wenzhou Zhang* and Liang Li*

Volume 17, Issue 1, 2022

Published on: 06 August, 2021

Page: [55 - 65] Pages: 11

DOI: 10.2174/1574892816666210806155754

Price: $65

Abstract

Background: In recent years, targeted therapy combined with traditional chemoradiotherapy and surgery has brought new opportunities for cancer treatment. However, the complex characteristics of cancer, such as heterogeneity and diversity, limit the clinical success of targeted drugs. Discovering of new cancer targets and deepening the understanding of their functional mechanisms will bring additional promising application prospects for the research and development of personalized cancer-targeted drugs.

Objectives: This study aimed to summarize the role of the Rho GTPase activating protein 9 (ARHGAP9) gene in tumorigenesis and development to discover therapeutic targets for cancer in the future.

Methods: For this review, we collected patents from the databases of Espacenet and WIPO and articles from PubMed that were related to the ARHGAP9 gene.

Results: Genetic/epigenetic variations and abnormal expression of the ARHGAP9 gene are closely associated with a variety of diseases, including cancer. ARHGAP9 can inactivate Rho GTPases by hydrolyzing GTP into GDP and regulate cancer cellular events, including proliferation, differentiation, apoptosis, migration and invasion, by inhibiting JNK/ERK/p38 and PI3K/AKT signaling pathways. In addition to reviewing these mechanisms, we assessed various patents on ARHGAP9 to determine whether ARHGAP9 might be used as a predictive biomarker for diagnosis/prognosis evaluation and a druggable target for cancer treatment.

Conclusion: In this review, the current knowledge of ARHGAP9 in cancer is summarized with an emphasis on its molecular function, regulatory mechanism and disease implications. Its characterization is crucial to understanding its important roles during different stages of cancer progression and therapy as a predictive biomarker and/or target.

Keywords: Cancer, Rho GTPase activating protein 9 (ARHGAP9), Rho GTPases, target, biomarker, treatment.

« Previous Next »
[1]
Nobes CD, Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 1999; 144(6): 1235-44.
[http://dx.doi.org/10.1083/jcb.144.6.1235] [PMID: 10087266]
[2]
Seoh ML, Ng CH, Yong J, Lim L, Leung T. ArhGAP15, a novel human RacGAP protein with GTPase binding property. FEBS Lett 2003; 539(1-3): 131-7.
[http://dx.doi.org/10.1016/S0014-5793(03)00213-8] [PMID: 12650940]
[3]
Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008; 582(14): 2093-101.
[http://dx.doi.org/10.1016/j.febslet.2008.04.039] [PMID: 18460342]
[4]
Paduch M, Jeleń F, Otlewski J. Structure of small G proteins and their regulators. Acta Biochim Pol 2001; 48(4): 829-50.
[http://dx.doi.org/10.18388/abp.2001_3850] [PMID: 11995995]
[5]
Cho HJ, Kim JT, Baek KE, Kim BY, Lee HG. Regulation of rho gtpases by rhogdis in human cancers. Cells 2019; 8(9): 1037.
[http://dx.doi.org/10.3390/cells8091037] [PMID: 31492019]
[6]
Haga RB, Ridley AJ. Rho GTPases: Regulation and roles in cancer cell biology. Small GTPases 2016; 7(4): 207-21.
[http://dx.doi.org/10.1080/21541248.2016.1232583] [PMID: 27628050]
[7]
Wu Y, Xu M, He R, Xu K, Ma Y. ARHGAP6 regulates the proliferation, migration and invasion of lung cancer cells. Oncol Rep 2019; 41(4): 2281-888.
[http://dx.doi.org/10.3892/or.2019.7031] [PMID: 30816546]
[8]
Wang T, Ha M. Silencing ARHGAP9 correlates with the risk of breast cancer and inhibits the proliferation, migration, and invasion of breast cancer. J Cell Biochem 2018; 119(9): 7747-56.
[http://dx.doi.org/10.1002/jcb.27127] [PMID: 29905031]
[9]
Li JP, Liu Y, Yin YH. ARHGAP1 overexpression inhibits proliferation, migration and invasion of C-33A and SiHa cell lines. OncoTargets Ther 2017; 10: 691-701.
[http://dx.doi.org/10.2147/OTT.S112223] [PMID: 28223826]
[10]
Johnstone CN, Castellví-Bel S, Chang LM, et al. ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers. Gene 2004; 336(1): 59-71.
[http://dx.doi.org/10.1016/j.gene.2004.01.025] [PMID: 15225876]
[11]
Zhang H, Tang QF, Sun MY, et al. ARHGAP9 suppresses the migration and invasion of hepatocellular carcinoma cells through up-regulating FOXJ2/E-cadherin. Cell Death Dis 2018; 9(9): 916.
[http://dx.doi.org/10.1038/s41419-018-0976-0] [PMID: 30206221]
[12]
Furukawa Y, Kawasoe T, Daigo Y, et al. Isolation of a novel human gene, ARHGAP9, encoding a rho-GTPase activating protein. Biochem Biophys Res Commun 2001; 284(3): 643-9.
[http://dx.doi.org/10.1006/bbrc.2001.5022] [PMID: 11396949]
[13]
Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J 2000; 348(Pt 2): 241-55.
[http://dx.doi.org/10.1042/bj3480241] [PMID: 10816416]
[14]
Hu KQ, Settleman J. Tandem SH2 binding sites mediate the RasGAP-RhoGAP interaction: a conformational mechanism for SH3 domain regulation. EMBO J 1997; 16(3): 473-83.
[http://dx.doi.org/10.1093/emboj/16.3.473] [PMID: 9034330]
[15]
Ang BK, Lim CY, Koh SS, et al. ArhGAP9, a novel MAP kinase docking protein, inhibits Erk and p38 activation through WW domain binding. J Mol Signal 2007; 2: 1.
[http://dx.doi.org/10.1186/1750-2187-2-1] [PMID: 17284314]
[16]
Ong SH, Ang BK. Use of ww protein domain for inhibiting activation of map kinases. WO2007113689, 2007.
[17]
Ceccarelli DF, Blasutig IM, Goudreault M, et al. Non-canonical interaction of phosphoinositides with pleckstrin homology domains of Tiam1 and ArhGAP9. J Biol Chem 2007; 282(18): 13864-74.
[http://dx.doi.org/10.1074/jbc.M700505200] [PMID: 17339315]
[18]
Anand K, Maeda K, Gavin AC. Structural analyses of the Slm1-PH domain demonstrate ligand binding in the non-canonical site. PLoS One 2012; 7(5): e36526.
[http://dx.doi.org/10.1371/journal.pone.0036526] [PMID: 22574179]
[19]
Moon SY, Zheng Y. Rho GTPase-activating proteins in cell regulation. Trends Cell Biol 2003; 13(1): 13-22.
[http://dx.doi.org/10.1016/S0962-8924(02)00004-1] [PMID: 12480336]
[20]
Anastassiou D, Watkinson J, Kim H. Biomarkers based on a multi-cancer invasion-associated machanism. US2011032356, 2011.
[21]
Bergstrom D, Dai XD, Hardwick J, et al. Expression profiles of biomarker genes in notch mediated cancers. EP20080795537, 2008.
[22]
Li L, Song WP, Zhao JY, et al. Usage of arhgap9 gene as a predictive marker for prognosis and chemoresistance of retinoblastoma. 201910671277, 2019.
[23]
Zhang K, Gao J, Ni Y. Screening of candidate key genes associated with human osteosarcoma using bioinformatics analysis. Oncol Lett 2017; 14(3): 2887-93.
[http://dx.doi.org/10.3892/ol.2017.6519] [PMID: 28928828]
[24]
Piao XM, Jeong P, Yan C, et al. A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncol Lett 2020; 19(1): 476-86.
[PMID: 31897161]
[25]
Park SH, Kim HJ, Ahn JG, Park CH, Yoon YM. Method for predicting prognosis of cancer. WO2014044848A1, 2015.
[26]
Li XQ, Pan RR, Shen YL, Zhang H, Zhang LJ. Human liver cancer marker and application thereof. CN110878355A, 2020.
[27]
Zhang LJ, Shen YL, Zhang H, et al. A biomarker for human liver cancer and its application. CN201811034587, 2018.
[28]
Song Y, Pan Y, Liu J. The relevance between the immune response-related gene module and clinical traits in head and neck squamous cell carcinoma. Cancer Manag Res 2019; 11: 7455-72.
[http://dx.doi.org/10.2147/CMAR.S201177] [PMID: 31496804]
[29]
Chen WX, Lou M, Cheng L, et al. Bioinformatics analysis of potential therapeutic targets among ARHGAP genes in breast cancer. Oncol Lett 2019; 18(6): 6017-25.
[http://dx.doi.org/10.3892/ol.2019.10949] [PMID: 31788076]
[30]
Lidereau R, Driouch K, Landemaine T. Method for predicting the occurrence of metastasis in breast cancer patients. EP20070300823, 2007.
[31]
Erlander MG, Ma XJ, Wang W, Wittliff JL. Breast cancer survival and recurrence. US2005010093, 2005.
[32]
Shi WW, Shen L, Gao J, et al. Assessment gene group and corresponding kit for prognostic prediction of gastric cancer. CN201910549657, 2019.
[33]
Gao J, Liu WJ, Shen L, et al. Compositions and methods for prognosis of gastric cancer. 2019; 2019 12/994411.
[34]
Sun L, Zhang Y, Lou J. ARHGAP9 siRNA inhibits gastric cancer cell proliferation and EMT via inactivating Akt, p38 signaling and inhibiting MMP2 and MMP9. Int J Clin Exp Pathol 2017; 10(12): 11979-85.
[PMID: 31966562]
[35]
Zhong J, Chen S, Xue M, et al. ZIC1 modulates cell-cycle distributions and cell migration through regulation of sonic hedgehog, PI(3)K and MAPK signaling pathways in gastric cancer. BMC Cancer 2012; 12: 290.
[http://dx.doi.org/10.1186/1471-2407-12-290] [PMID: 22799764]
[36]
Han C, He S, Wang R, et al. The role of ARHGAP9: Clinical implication and potential function in acute myeloid leukemia. J Transl Med 2021; 19(1): 65.
[http://dx.doi.org/10.1186/s12967-021-02733-5] [PMID: 33579308]
[37]
Sun MY, Song YN, Zhang M, Zhang CY, Zhang LJ, Zhang H. Ginsenoside Rg3 inhibits the migration and invasion of liver cancer cells by increasing the protein expression of ARHGAP9. Oncol Lett 2019; 17(1): 965-73.
[PMID: 30655855]
[38]
Liu JP, Zhang M, Zhang H, Zhao B. Experimental study on the effect and mechanism of casticin on the invasion and migration of hepatocellular carcinoma cell hepg2 (in chinese). Hebei J TCM 2018; 40(3): 416-20.
[39]
Song WP, Zhang CY, Zhang Y, et al. Generation of etoposide-resistant subline of human retinoblastoma y79 cells and preliminary study on the mechanism of drug resistance (in chinese). Chin Med Biotechnol 2017; 12: 297-302.
[40]
Song WP, Zheng S, Yao HJ, et al. Different transcriptome profiles between human retinoblastoma Y79 cells and an etoposide-resistant subline reveal a chemoresistance mechanism. BMC Ophthalmol 2020; 20(1): 92.
[http://dx.doi.org/10.1186/s12886-020-01348-6] [PMID: 32143590]
[41]
Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 2013; 14(4): R36.
[http://dx.doi.org/10.1186/gb-2013-14-4-r36] [PMID: 23618408]
[42]
Lange AM, Lo HW. Inhibiting trk proteins in clinical cancer therapy. Cancers (Basel) 2018; 10(4): 105.
[http://dx.doi.org/10.3390/cancers10040105] [PMID: 29617282]
[43]
Peluso I, Yarla NS, Ambra R, Pastore G, Perry G. MAPK signalling pathway in cancers: Olive products as cancer preventive and therapeutic agents. Semin Cancer Biol 2019; 56: 185-95.
[http://dx.doi.org/10.1016/j.semcancer.2017.09.002] [PMID: 28912082]
[44]
Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 2015; 15(1): 7-24.
[http://dx.doi.org/10.1038/nrc3860] [PMID: 25533673]
[45]
Sharma VR, Gupta GK, Sharma AK, et al. Pi3k/akt/mtor intracellular pathway and breast cancer: Factors, mechanism and regulation. Curr Pharm Des 2017; 23(11): 1633-8.
[http://dx.doi.org/10.2174/1381612823666161116125218] [PMID: 27848885]
[46]
Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The pi3k pathway in human disease. Cell 2017; 170(4): 605-35.
[http://dx.doi.org/10.1016/j.cell.2017.07.029] [PMID: 28802037]
[47]
Degirmenci B, Valenta T, Dimitrieva S, Hausmann G, Basler K. GLI1-expressing mesenchymal cells form the essential Wnt-secreting niche for colon stem cells. Nature 2018; 558(7710): 449-53.
[http://dx.doi.org/10.1038/s41586-018-0190-3] [PMID: 29875413]
[48]
Katoh Y, Katoh M. Integrative genomic analyses on GLI1: positive regulation of GLI1 by Hedgehog-GLI, TGFbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. Int J Oncol 2009; 35(1): 187-92.
[http://dx.doi.org/10.3892/ijo_00000328] [PMID: 19513567]
[49]
Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996; 273(5272): 245-8.
[http://dx.doi.org/10.1126/science.273.5272.245] [PMID: 8662509]
[50]
Takefuji M, Asano H, Mori K, et al. Mutation of ARHGAP9 in patients with coronary spastic angina. J Hum Genet 2010; 55(1): 42-9.
[http://dx.doi.org/10.1038/jhg.2009.120] [PMID: 19911011]
[51]
Carless MA, Kulkarni H, Kos MZ, et al. Genetic effects on DNA methylation and its potential relevance for obesity in Mexican Americans. PLoS One 2013; 8(9): e73950.
[http://dx.doi.org/10.1371/journal.pone.0073950] [PMID: 24058506]
[52]
Haas BE, Horvath S, Pietiläinen KH, et al. Adipose co-expression networks across Finns and Mexicans identify novel triglyceride-associated genes. BMC Med Genomics 2012; 5: 61.
[http://dx.doi.org/10.1186/1755-8794-5-61] [PMID: 23217153]
[53]
Shen H, Liang Z, Zheng S, Li X. Pathway and network-based analysis of genome-wide association studies and RT-PCR validation in polycystic ovary syndrome. Int J Mol Med 2017; 40(5): 1385-96.
[http://dx.doi.org/10.3892/ijmm.2017.3146] [PMID: 28949383]
[54]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68(1): 7-30.
[http://dx.doi.org/10.3322/caac.21442] [PMID: 29313949]
[55]
Srdic D, Plestina S, Sverko-Peternac A, Nikolac N, Simundic AM, Samarzija M. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Support Care Cancer 2016; 24(11): 4495-502.
[http://dx.doi.org/10.1007/s00520-016-3287-y] [PMID: 27236439]
[56]
Showe M, Showe L, Yousef M, et al. Method for diagnosing lung cancers gene expression profiles in peripheral blood mononuclear cells. US Patent 2010255486, 2010.

Rights & Permissions Print Cite
Article Metrics
28
1
© 2024 Bentham Science Publishers | Privacy Policy